Medlive Technology's 2026 Business Outlook Appears Constructive -- Market Talk

Dow Jones

Apr 01

0620 GMT - Medlive Technology's 2026 business outlook appears constructive, UOB Kay Hian analysts say in a research report. Management has guided for 20% growth in healthcare product count for 2026, signaling continued market-share gains amid faster innovative drug launches and stricter compliance, the analysts note. Backed by AI-enabled margin expansion and steady research and development, the online professional physician platform operator is positioned to capture China's 17 billion-yuan digital healthcare marketing opportunity. The brokerage maintains the stock's buy rating but lowers the target price to HK$11.00 from HK$13.50 to reflect more conservative valuation multiple amid rising geopolitical tensions. Shares are 1.8% higher at HK$8.63. (ronnie.harui@wsj.com)

(END) Dow Jones Newswires

April 01, 2026 02:20 ET (06:20 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/2624629245"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624629245\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624629245?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-01 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624629245","market":"sg","top_or_hot":-1,"title":"Medlive Technology's 2026 Business Outlook Appears Constructive -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0620 GMT - Medlive Technology's 2026 business outlook appears constructive, UOB Kay Hian analysts say in a research report. Management has guided for 20% growth in healthcare product count for 2026, signaling continued market-share gains amid faster innovative drug launches and stricter compliance, the analysts note. Backed by AI-enabled margin expansion and steady research and development, the online professional physician platform operator is positioned to capture China's 17 billion-yuan digital healthcare marketing opportunity. The brokerage maintains the stock's buy rating but lowers the target price to HK$11.00 from HK$13.50 to reflect more conservative valuation multiple amid rising geopolitical tensions. Shares are 1.8% higher at HK$8.63. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2026 02:20 ET (06:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Medlive Technology's 2026 Business Outlook Appears Constructive -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMedlive Technology's 2026 Business Outlook Appears Constructive -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-01 14:20</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0620 GMT - Medlive Technology's 2026 business outlook appears constructive, UOB Kay Hian analysts say in a research report. Management has guided for 20% growth in healthcare product count for 2026, signaling continued market-share gains amid faster innovative drug launches and stricter compliance, the analysts note. Backed by AI-enabled margin expansion and steady research and development, the online professional physician platform operator is positioned to capture China's 17 billion-yuan digital healthcare marketing opportunity. The brokerage maintains the stock's buy rating but lowers the target price to HK$11.00 from HK$13.50 to reflect more conservative valuation multiple amid rising geopolitical tensions. Shares are 1.8% higher at HK$8.63. (ronnie.harui@wsj.com) \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 01, 2026 02:20 ET (06:20 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1189","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2624629245","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624629245","pubTimestamp":1775024400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0620 GMT - Medlive Technology's 2026 business outlook appears constructive, UOB Kay Hian analysts say in a research report. Management has guided for 20% growth in healthcare product count for 2026, signaling continued market-share gains amid faster innovative drug launches and stricter compliance, the analysts note. Backed by AI-enabled margin expansion and steady research and development, the online professional physician platform operator is positioned to capture China's 17 billion-yuan digital healthcare marketing opportunity. The brokerage maintains the stock's buy rating but lowers the target price to HK$11.00 from HK$13.50 to reflect more conservative valuation multiple amid rising geopolitical tensions. Shares are 1.8% higher at HK$8.63. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1189":"医疗保健技术","LU1235295612.USD":"FIDELITY PACIFIC \"A\" (USDHDG) INC","LU0049112450.USD":"FIDELITY PACIFIC \"A\" INC","LU1046422090.SGD":"Fidelity Pacific A-SGD","BK1587":"次新股","02192":"医脉通"},"translate_title":"MedLive Technology 2026年业务前景具有建设性——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02192":0.9},"content_text":"0620 GMT - Medlive Technology's 2026 business outlook appears constructive, UOB Kay Hian analysts say in a research report. Management has guided for 20% growth in healthcare product count for 2026, signaling continued market-share gains amid faster innovative drug launches and stricter compliance, the analysts note. Backed by AI-enabled margin expansion and steady research and development, the online professional physician platform operator is positioned to capture China's 17 billion-yuan digital healthcare marketing opportunity. The brokerage maintains the stock's buy rating but lowers the target price to HK$11.00 from HK$13.50 to reflect more conservative valuation multiple amid rising geopolitical tensions. Shares are 1.8% higher at HK$8.63. (ronnie.harui@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 02:20 ET (06:20 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}